Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia
Open accessAbstract
SUMMARY: It has been suggested that the humoral immune system plays a role in the pathogenesis of non-specific interstitial pneumonia (NSIP). Although some circulating autoantibodies to cytoskeletal protein(s) have been suggested, the antimyofibroblast antibody has not been investigated in patients with idiopathic pulmonary fibrosis (IPF) and NSIP. The purpose of this study is to evaluate the existence of antimyofibroblast antibody in the sera of patients with IPF and NSIP. The MRC5 cell line was used as a model of myofibroblast. The anti-MRC5 cell antibody was characterized in a patient with NSIP using Western blotting. Since we found that one of the anti-MRC5 antibodies was an antivimentin antibody, we established an enzyme-linked immunosorbent assay (ELISA) to measure the levels of antivimentin antibody in the sera of patients with IPF (n = 12) and NSIP (n = 23). Initially, two anti-MRC5 cell antibodies were detected in the sera of patients with NSIP, one of which was characterized as the antivimentin antibody by Western blotting. The other was characterized as an antivimentin fragment antibody. We established an ELISA to measure the antivimentin antibody and found significantly higher levels in patients with IPF and NSIP than in normal volunteers. One of the anti-MRC5 cell antibodies in the serum of a patient with NSIP was against vimentin. The serum levels of antivimentin antibody were increased in patients with IPF and NSIP compared with that of normal volunteers. These results suggest that the antivimentin antibody may be involved in the process of lung injury in IPF and NSIP.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A variety of novel autoantibodies targeting neoepitopes have been reported in IPF, with many targets being structural cell proteins such as desmoplakin and periplakin.
“A variety of novel autoantibodies targeting neoepitopes have been reported in IPF (159–163), with many of the targets being structural cell proteins, such as desmoplakin (164) and periplakin (159).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [162]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 36 · Cited by 62
- Authors
- YANG, Y., FUJITA, J., BANDOH, S., OHTSUKI, Y., YAMADORI, I., YOSHINOUCHI, T., & ISHIDA, T.
- Affiliations
- China Medical University (TW)
- Kagawa University (JP)
- Kochi Medical School Hospital (JP)
- Okayama Medical Center (JP)
- Nagoya City University (JP)
- Corresponding author
- FUJITA, J
- Venue
- Clinical and Experimental Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-04
- Volume
- 128
- Issue
- 1
- Pages
- 169-174
- ISSN
- 0009-9104 (ISSN-L)
- 1365-2249
- PMC
- PMC1906354
- OpenAlex
- W1990883267
- Cited by
- 62
- References
- 36
- Citations by year
- 2026: 2 · 2024: 1 · 2023: 4 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 4 · 2017: 4 · 2016: 3 · 2015: 1 · 2014: 3 · 2013: 6 · 2012: 2
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Clinical & Experimental Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pathology and Forensic Medicine › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, vimentin, myofibroblasts, autoantibodies, humoral immunity, lung injury, MRC-5 cells, cytoskeletal proteins
- MeSH terms
- Autoantibodies, Cell Line, Enzyme-Linked Immunosorbent Assay, Fibroblasts, Humans, Muscles, Pulmonary Fibrosis, Vimentin, Lung Diseases, Interstitial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
